Bowman-Birk inhibitors, proteasome peptidase activities and colorectal pre neoplasias induced by 1,2-dimethylhydrazine in Swiss mice

Food and Chemical Toxicology

Volumn 50, Issue 5, 2012, Pages 1405-1412

  de Paula Carli, Alessandra ^a,b   de Abreu Vieira, Paula Melo ^a   Silva, Karina Taciana Santos ^a   de Sá Cota, Renata Guerra ^a   Carneiro, Cláudia Martins ^a   Castro Borges, William ^a   de Andrade, Milton Hércules Guerra ^a  

^a FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^b Centro Universitário de Caratinga   (Brazil)

Author keywords

Bowman Birk inhibitors; CD44; Colon cancer; Dimethylhydrazine; Proteasome activity

Indexed keywords

1,2 DIMETHYLHYDRAZINE; BOWMAN BIRK INHIBITOR; CHYMOTRYPSIN; HERMES ANTIGEN; PEPTIDASE; PROTEASOME; TRYPSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER PREVENTION; CELL FRACTIONATION; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; GASTROINTESTINAL DYSPLASIA; HISTOPATHOLOGY; INTESTINE CELL; LYSOSOME; MACROTYLOMA AXILLARE; MALE; MEDICINAL PLANT; MOUSE; NONHUMAN; PRECANCER; SOYBEAN; TREATMENT DURATION;

1,2-DIMETHYLHYDRAZINE; ANIMALS; ANTIGENS, CD44; BLOTTING, WESTERN; CARCINOGENS; CHROMATOGRAPHY, GEL; COLORECTAL NEOPLASMS; MALE; MICE; PRECANCEROUS CONDITIONS; PROTEASOME ENDOPEPTIDASE COMPLEX; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN;

ANIMALIA; GLYCINE MAX; MACROTYLOMA AXILLARE; MUS;

EID: 84858162528     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.01.036     Document Type: Article

References (39)

1. Arcinas A., Yen T.Y., Kebebew E., Macher B.A. Cell surface and secreted protein profiles of human thyroid cancer cell lines reveal distinct glycoprotein patterns. J. Proteome Res. 2009, 8(8):3958-3968.
2. Billings P.C., Brandon D.L., Habres J.M. Internalisation of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur. J. Cancer 1991, 27(7):903-908.
3. Billings P.C., Newberne P.M., Kennedy A.R. Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 1990, 11(7):1083-1086.
4. Billings P.C., St Clair W., Owen A.J., Kennedy A.R. Potential intracellular target proteins of the anticarcinogenic Bowman Birk protease inhibitor identified by affinity chromatography. Cancer Res. 1988, 48(7):1798-1802.
5. Brown R.L., Reinke L.M., Damerow M.S., Perez D., Chodosh L.A., Yang J., Cheng C. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J. Clin. Invest. 2011, 121(3):1064-1074.
6. Cavo M. Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006, 20(8):1341-1352.
7. César J., de Santana M., de Oliveira M., Santos A., de Miranda A., Santoro M., de Andrade M. A New Extraction and Purification Methodology of Bowman-Birk Inhibitors from Seeds and Germinated Seeds of<i> Macrotyloma axillare</i>. Chromatographia 2009, 69(3):357-360.
8. Chen D., Frezza M., Schmitt S., Kanwar J. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr. Cancer Drug Targets 2011, 11(3):239-253.
9. Chen Y.W., Huang S.C., Lin-Shiau S.Y., Lin J.K. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 2005, 26(7):1296-1306.
10. Deshimaru M., Yoshimi S., Shioi S., Terada S. Multigene family for Bowman-Birk type proteinase inhibitors of wild soja and soybean: the presence of two BBI-A genes and pseudogenes. Biosci. Biotechnol. Biochem. 2004, 68(6):1279-1286.
11. Forman M.R., Hursting S.D., Umar A., Barrett J.C. Nutrition and cancer prevention: a multidisciplinary perspective on human trials. Annu. Rev. Nutr. 2004, 24:223-254.
12. Gariani T., McBride J.D., Leatherbarrow R.J. The role of the P2' position of Bowman-Birk proteinase inhibitor in the inhibition of trypsin. Studies on P2' variation in cyclic peptides encompassing the reactive site loop. Biochim. Biophys. Acta 1999, 1431(1):232-237.
13. Godge P.Y., Poonja L.S. Quantitative assessment of expression of cell adhesion molecule (CD44) splice variants: CD44 standard (CD44s) and v5, v6 isoforms in oral leukoplakias: An immunohistochemical study. Indian J. Dent. Res. 2011, 22(3):493-494.
14. Gomes C.E., Barbosa A.E., Macedo L.L., Pitanga J.C., Moura F.T., Oliveira A.S., Moura R.M., Queiroz A.F., Macedo F.P., Andrade L.B., Vidal M.S., Sales M.P. Effect of trypsin inhibitor from Crotalaria pallida seeds on Callosobruchus maculatus (cowpea weevil) and Ceratitis capitata (fruit fly). Plant Physiol. Biochem. 2005, 43(12):1095-1102.
15. Hanley W.D., Napier S.L., Burdick M.M., Schnaar R.L., Sackstein R., Konstantopoulos K. Variant isoforms of CD44 are P- and L-selectin ligands on colon carcinoma cells. FASEB J. 2006, 20(2):337-339.
16. Hernandez-Ledesma B., Hsieh C.C., de Lumen B.O. Lunasin and Bowman-Birk protease inhibitor (BBI) in US commercial soy foods. Food Chem. 2009, 115(2):574-580.
17. Hynes M.J., Huang K.M., Huang E.H. Review paper: Implications of the " cancer stem cell" hypothesis on murine models of colon cancer and colitis-associated cancer. Vet. Pathol. 2009, 46(5):819-835.
18. Joubert F.J., Kruger H., Townshend G.S., Botes D.P. Purification, some properties and the complete primary structures of two protease inhibitors (DE-3 and DE-4) from Macrotyloma axillare seed. Eur. J. Biochem. 1979, 97(1):85-91.
19. Kennedy A.R. Chemopreventive agents: protease inhibitors. Pharmacol. Ther. 1998, 78(3):167-209.
20. Kennedy A.R., Beazer-Barclay Y., Kinzler K.W., Newberne P.M. Suppression of carcinogenesis in the intestines of min mice by the soybean-derived Bowman-Birk inhibitor. Cancer Res. 1996, 56(4):679-682.
21. Kennedy A.R., Billings P.C., Wan X.S., Newberne P.M. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis. Nutr. Cancer 2002, 43(2):174-186.
22. Kennedy A.R., Davis J.G., Carlton W., Ware J.H. Effects of dietary antioxidant supplementation on the development of malignant lymphoma and other neoplastic lesions in mice exposed to proton or iron-ion radiation. Radiat. Res. 2008, 169(6):615-625.
23. Kisselev A.F., Callard A., Goldberg A.L. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J. Biol. Chem. 2006, 281(13):8582-8590.
24. Kris-Etherton P.M., Hecker K.D., Bonanome A., Coval S.M., Binkoski A.E., Hilpert K.F., Griel A.E., Etherton T.D. Bioactive compounds in foods: their role in the prevention of cardiovascular disease and cancer. Am. J. Med. 2002, 113(9B):71S-88S.
25. Kumar P., Sreerama Y.N., Gowda L.R. Formation of Bowman-Birk inhibitors during the germination of horsegram (Dolichos biflorus). Phytochemistry 2002, 60(6):581-588.
26. Losso J.N. The biochemical and functional food properties of the bowman-birk inhibitor. Crit. Rev. Food Sci. Nutr. 2008, 48(1):94-118.
27. Matsumoto I., Kitagaki H., Akai Y., Ito Y., Seno N. Derivatization of epoxy-activated agarose with various carbohydrates for the preparation of stable and high-capacity affinity adsorbents - their use for affinity-chromatography of carbohydrate-binding proteins. Anal. Biochem. 1981, 116(1):103-110.
28. Mitsiades N., Mitsiades C.S., Poulaki V., Chauhan D., Fanourakis G., Gu X., Bailey C., Joseph M., Libermann T.A., Treon S.P., Munshi N.C., Richardson P.G., Hideshima T., Anderson K.C. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Natl. Acad. Sci. USA 2002, 99(22):14374-14379.
29. Montagut C., Rovira A., Albanell J. The proteasome: a novel target for anticancer therapy. Clin. Transl. Oncol. 2006, 8(5):313-317.
30. Myung J., Kim K.B., Crews C.M. The ubiquitin-proteasome pathway and proteasome inhibitors. Med. Res. Rev. 2001, 21(4):245-273.
31. Odani S., Ikenaka T. Scission of soybean Bowman-Birk proteinase inhibitor into two small fragments having either trypsin or chymotrypsin inhibitory activity. J. Biochem. 1973, 74(4):857-860.
32. Saito T., Sato H., Virgona N., Hagiwara H., Kashiwagi K., Suzuki K., Asano R., Yano T. Negative growth control of osteosarcoma cell by Bowman-Birk protease inhibitor from soybean; involvement of connexin 43. Cancer Lett. 2007, 253(2):249-257.
33. Santana M.A., Castro-Borges W., Amorin L.L., Santos A.G., Cristine Leal S., Andrade M.H.G. Perennial Horse Gram (Macrotyloma axillare) Seeds: biotechnology applications of its peptide and protein content - Bowman-Birk inhibitors and lectin. Nuts & Seeds in Health and Disease Prevention 2011, 899-907. Burlington, San Diego, London. 1st ed. V.R. Preedy, R.R. Watson, V.B. Patel (Eds.).
34. St Clair W.H., Billings P.C., Carew J.A., Keller-McGandy C., Newberne P., Kennedy A.R. Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res. 1990, 50(3):580-586.
35. Sugahara K.N., Hirata T., Tanaka T., Ogino S., Takeda M., Terasawa H., Shimada I., Tamura J., ten Dam G.B., van Kuppevelt T.H., Miyasaka M. Chondroitin sulfate E fragments enhance CD44 cleavage and CD44-dependent motility in tumor cells. Cancer Res. 2008, 68(17):7191-7199.
36. Tanaka K. The proteasome: overview of structure and functions. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 2009, 85(1):12-36.
37. Towbin H., Staehelin T., Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. USA 1979, 76(9):4350-4354.
38. Wang S.J., Wong G., de Heer A.M., Xia W., Bourguignon L.Y. CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 2009, 119(8):1518-1530.
39. Yavelow J., Collins M., Birk Y., Troll W., Kennedy A.R. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress X-ray-induced transformation in vitro. Proc. Natl. Acad. Sci. USA 1985, 82(16):5395-5399.